A biotech start-up stock entering the ASX200 with an IP not even close to Ph2 clinical trial completion let alone commercialisation unsurprisingly got smashed (what did I tell you then) and the MC at that time was higher than NEU and CU6 MC at their highest. Why? Because of the potential market for cancer treatment.
The fundamental has strengthen for IMU since then after completion of Ph2 clinical trial with very good final result released early last year, excellent clinical trial update for VAXINIA which saw them receive Fast Track designation and ODD from the FDA within only 12-18 months of clinical trial and excellent clinical trial update for Azer-Cel. The share holders who know this are buying as they are given another opportunity to average down or enter big time but unlike last year, there's a lot of clinical trial updates to be released this year which the pps will move the market. It's all about the clinical trial updates for biotech start-up stock (always has been and always will be), look at what happened to the pps after the excellent clinical trial update for VAXINIA and Azer-Cel (this recent drop from this announcement is very surprising and interesting though.........) but IMU need sustain updates which will happen this year.
IMU Price at posting:
4.0¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)